Kyntra Bio (KYNB) Share-based Compensation (2014 - 2026)
Kyntra Bio (KYNB) posted Share-based Compensation of $1.2 million for Q1 2026, up 121.64% sequentially from -$5.3 million in Q4 2025, and down 59.64% YoY from $2.9 million in Q1 2025.
Kyntra Bio (KYNB) Share-based Compensation (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Share-based Compensation for 13 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Share-based Compensation fell 59.64% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 153.46% YoY) and the FY2025 annual result came in at $3.6 million, down 48.57% from the prior year.
- Share-based Compensation improved to $1.2 million in Q1 2026 per KYNB's latest filing, from -$5.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $61.0 million in Q4 2022 and troughed at -$32.0 million in Q3 2023.
- A 5-year average of $4.2 million and a median of $195000.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 4709.01% in 2025, down 38085.71% in 2025.
- Over 5 years, Share-based Compensation stood at $61.0 million in 2022, then plunged by 99.61% to $237000.0 in 2023, then sank by 94.09% to $14000.0 in 2024, then tumbled by 38085.71% to -$5.3 million in 2025, then jumped by 121.64% to $1.2 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.2 million, -$5.3 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | - |
| 10 | Kyntra Bio | 29.67 Mn | 29.67 Mn | 1.47 Mn | 984,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 984,000.00 |
| Jun 30, 2026 | 984,000.00 |
| Mar 31, 2026 | 1.15 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | -5.32 Mn |
| Dec 31, 2025 | -5.32 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Mar 31, 2024 | 153,000.00 |